Our history

Catalent Pharma Solutions was created in April 2007, when The Blackstone Group, a financial advisory firm, acquired the Pharmaceutical Technologies and Services segment of Cardinal Health. Catalent has nearly 75 years of experience in serving pharmaceutical and consumer health companies around the globe, and nearly 20 years of experience in serving the biotechnology industry.

We were formed by Cardinal through a series of acquisitions in order to provide a broad range of specialized, market-leading solutions for the pharmaceutical, biotechnology and consumer health industry. In 1996, Cardinal acquired PCI Services, Inc., which was the market leader in the outsourced packaging for prescription and over-the-counter pharmaceuticals, veterinary and other products. Two years later, Cardinal acquired R.P. Scherer Corp., the market leader in advanced oral drug delivery technologies which commercialized softgel manufacturing in the 1930s. In order to participate in the important sterile dose form market, in 1999, Cardinal acquired Automatic Liquid Packaging, Inc., the market leader in blow-fill-seal technology for respiratory treatments, ophthalmics and other areas. In 2001, we continued our expansion with two acquisitions, SP Pharmaceuticals, LLC, a provider of sterile fill/finish manufacturing and lyophilization services for injectables, and International Processing Corporation, which provided us with oral solid coating and dose manufacturing capabilities. In 2002, we entered the fee-for-service analytical chemistry market with the acquisition of Magellan Labs, a leader in the analytical sciences services to the U.S. pharmaceuticals industry. Finally, in 2003, Cardinal acquired Intercare Group PLC, from which we expanded our European manufacturing network. Between 2003 and 2006, we also made other selective acquisitions of businesses, facilities and technologies in the oral manufacturing, packaging services and other areas.

Catalent’s history of innovation in the advanced delivery and packaging of drugs forms the foundation of our market-leading business. We have a track record of more than seven decades of oral dose form innovation since we commercialized softgel manufacturing in the 1930s. We launched the “fast-dissolve” dose form category by commercializing our Zydis® technology in the 1980s and introduced a vegetable-based softgel shell system, VegiCaps® Soft, in 2001. We also have three decades of packaging innovation experience in patient and physician sample kits, innovative child resistant/senior-friendly designs, unit dose technology (DelPouch®/DelStrip™) and compliance-enhancing packaging. Today we employ more than 1,000 scientists and technicians, and hold over 1,000 patents and patent applications in advanced drug delivery, biologics formulation, manufacturing and packaging.